<p>In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome back Christine M. Lovly, MD, PhD, to talk about the complexities of treating advanced EGFR-positive NSCLC. Dr. Lovely shares how she talks with patients about the latest data and recent trials.</p>

In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome back Christine M. Lovly, MD, PhD, to talk about the complexities of treating advanced EGFR-positive NSCLC. Dr. Lovely shares how she talks with patients about the latest data and recent trials.

“What I Tell My Patients”: Making Sense of New Treatment Options in EGFR-positive NSCLC

LungCancerRx is a new podcast that features conversations among oncologists and patients. From tackling logistical obstacles to handling existential questions, these discussions aim to provide empowerment, knowledge, and hope across the lung cancer community. Eric K. Singhi, MD, a thoracic oncologist in Houston; Aakash Desai, MD, MPH, an assistant professor at the University of Alabama Birmingham’s O’Neal Cancer Center; and Fawzi Abu Rous, MD, a thoracic medical oncologist at Henry Ford Health in Detroit, cohost each episode. “We wanted to bridge the gap between provider communication and patient communication,” explains Dr. Singhi.

Share “What I Tell My Patients”: Making Sense of New Treatment Options in EGFR-positive NSCLC

Sign up to save your podcasts

“What I Tell My Patients”: Making Sense of New Treatment Options in EGFR-positive NSCLC

“What I Tell My Patients”: Making Sense of New Treatment Options in EGFR-positive NSCLC

More shows like Lung Cancer Rx

Lung Cancer Considered